Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > NADIM: Risk of progression identified through RNA sequencing

NADIM: Risk of progression identified through RNA sequencing

Presented By
Ms Marta Casarrubios, Hospital Universitario Puerta de Hierro-Majadahonda, Spain
Conference
WCLC 2022
Trial
Phase 2, NADIM
Doi
https://doi.org/10.55788/411391f4
In individuals who did not achieve complete pathological response (CPR) from the phase 2 NADIM trial, an immune expression signature was identified that was associated with disease progression [1]. According to the authors, these results could help in the follow-up and management of patients with resectable non-small cell lung cancer (NSCLC). The phase 2 NADIM trial (NCT03081689) investigated the safety and efficacy of neoadjuvant chemotherapy plus nivolumab in 46 patients with stage IIIA, resectable NSCLC. The positive results of this trial were previously published in The Lancet Oncology [2]. Through RNA sequencing, the current analysis aimed to identify biomarkers of disease progression in patients that had received surgery in this trial (n=36). Ms Marta Casarrubios (Hospital Universitario Puerta de Hierro-Majadahonda, Spain) presented the findings....


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on